Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases. TAFIa level in patients with IBD

Journal of Crohn's and Colitis

Volumn 6, Issue 1, 2012, Pages 13-20

  Owczarek, Danuta ^a   Undas, Anetta ^a   Foley, Jonathan H ^b   Nesheim, Michael E ^a,b   Jabłonski, Konrad ^a   Mach, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Carboxypeptidase u; Inflammation; Inflammatory bowel disease; TAFI

Indexed keywords

ACTIVATED THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; ALBUMIN; C REACTIVE PROTEIN; CORTICOSTEROID; FIBRINOGEN; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; CARBOXYPEPTIDASE U; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84855948565     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.06.005     Document Type: Article

References (35)

1. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430.
2. Tsiolakidou G., Koutroubakis I.E. Trombosis and inflammatory bowel disease-the role of genetic risk factors. World J Gastroenterol 2008, 14:4440-4444.
3. Papa A., Scaldaferri F., Danese S., Guglielmo S., Roberto I., Bonizzi M., Mocci G., Felice C., Ricci C., Andrisani G., Fedeli G., Gasbarrini G., Gasbarrini A. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 2008, 26:149-155.
4. Silveira A., Schatteman K., Goossens F., Moor E., Scharpé S., Strömqvist M., Hendriks D., Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000, 84:364-368.
5. Rooth E., Wallen H., Antovic A., von Arbin M., Kaponides G., Wahlgren N., Blomback M., Antovic J. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis 2007, 18:365-370.
6. Donmez A., Aksu K., Celik H.A., Keser G., Cagirgan S., Omay S.B., Inal V., Aydin H.H., Tombuloglu M., Doganavsargil E. Thrombin activatable fibrinolysis inhibitor in Behcet's disease. Thromb Res 2005, 115:287-292.
7. Peters M.J., Nurmohamed M.T., van Eijk I.C., Verkleij C.J., Marx P.F. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1232-1233.
8. Yano Y., Kitagawa N., Gabazza E.C., Morioka K., Urakawa H., Tanaka T., Katsui A., Araki-Sasaki R., Hori Y., Nakatani K., Taguchi O., Sumida Y., Adachi Y. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003, 88:736-741.
9. Bajzar L., Nesheim M.E., Tracy P.B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996, 88:2093-2100.
10. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996, 271:16603-16608.
11. Wang W., Boffa M.B., Bajzar L., Walker J.B., Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998, 273:27176-27181.
12. Leung L.L., Nishimura T., Myles T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol 2008, 632:61-69.
13. Saibeni S., Bottasso B., Spina L., Bajetta M., Danese S., Gasbarrini A., de Franchis R., Vecchi M. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004, 99:1966-1970.
14. Koutroubakis I.E., Sfiridaki A., Tsiolakidou G., Coucoutsi C., Theodoropoulou A., Kouroumalis E.A. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008, 20:912-916.
15. Stenson W.F. Inflammatory bowel diseases. Textbook of gastroenterology 1995, Vol. 2:1761-1772. JB Lippincott, Philadelphia. 2nd ed. T. Yamada (Ed.).
16. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
17. Rentsch M., Beham A., Schlitt H.J., Jauch K.W. Crohn's disease activity index and Vienna classification-is it worthwhile to calculate before surgery?. Dig Surg 2006, 23:241-249.
18. van Deventer S.J., Tami J.A., Wedel M.K. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004, 53:1646-1651.
19. Owczarek D., Cibor D., Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010, 16:52-57.
20. Malm L., Laurell M., Dahlback B. Changes in the plasma levels of vitamin-K dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988, 68:437-443.
21. Kim P.Y., Foley J., Hsu G., Kim P.Y., Nesheim M.E. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2008, 372:32-40.
22. Hataji O., Taguchi O., Gabazza E.C., Yuda H., D'Alessandro-Gabazza C.N., Fujimoto H., Nishii Y., Hayashi T., Suzuki K., Adachi Y. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004, 76:214-219.
23. Brouns R., Heylen E., Willemse J.L., Sheorajpanday R., De Surgeloose D., Verkerk R., De Deyn P.P., Hendriks D.F. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 2010, 8:75-80.
24. Tregouet D.A., Schnabel R., Alessi M.C., Godefroy T., Declerck P.J., Nicaud V., Munzel T., Bickel C., Rupprecht H.J., Lubos E., Zeller T., Juhan-Vague I., Blankenberg S., Tiret L., Morange P.E. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2009, 7:49-57.
25. Te Velde E.A., Wagenaar G.T., Reijerkerk A., Roose-Girma M., Borel R.I., Voest E.E., Bouma B.N., Gebbink M.F., Meijers J.C. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003, 1:2087-2096.
26. Kawamura T., Okada N., Okada H. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol 2002, 46:225-230.
27. van Aken B.E., Reitsma P.H., Rosendaal F.R. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002, 116:173-177.
28. Van de Wouwer M., Collen D., Conway E.M. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004, 24:1374-1383.
29. Myles T., Nishimura T., Yun T.H., Nagashima M., Morser J., Patterson A.J., Pearl R.G., Leung L.L. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003, 278:51059-51067.
30. Kume K., Yamasaki M., Tashiro M., Yoshikawa I., Otsuki M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med 2007, 46:1323-1329.
31. Kjeldsen J., Lassen J.F., Brandslund I., Schaffalitzky de Muckadell O.B. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998, 33:637-643.
32. Marks D.J., Harbord M.W., MacAllister R., Rahman F.Z., Young J., Al Lazikani B., Lees W., Novelli M., Bloom S., Segal A.W. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006, 367:668-678.
33. Moss A.C., Farrell R.J. Impotent immune system: an underlying problem in Crohn's disease. Gastroenterology 2007, 132:2609-2611.
34. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002, 277:1021-1030.
35. Foley J.H., Kim P.Y., Nesheim M.E. TAFI zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008, 283:8863-8867.